Parkinson's Disease Neuroprotection Clinical Trial

描述(由申请人提供)：帕金森氏症治疗的下一个量子进步将是减缓疾病进展的治疗方法的发展。新药物的测试将需要招募最近诊断为帕金森氏症的受试者，并将他们保留在为期五到十年的治疗试验中。俄勒冈州俄勒冈健康与科学大学帕金森中心在进行临床试验方面的丰富经验，特别是在最近诊断的受试者中进行的长期试验，支持我们参与帕金森病神经保护剂的多中心合作试验。我们还提出了一些方法，通过这些方法，我们可以增加新受试者的入学人数，包括来自少数群体的受试者，并将他们保留在研究中。 此外，早期帕金森氏症神经保护剂的长期试验提供了一个独特的机会，可以研究家庭护理的自然历史，评估照顾者压力作为新疗法的结果变量，并确定减少护理压力的潜在干预措施。这些研究将延伸和扩大我们在帕金森研究小组DATATOP队列中所做的关于帕金森病家庭护理的初步研究。

DESCRIPTION (provided by applicant): The next quantum step forward in the treatment of Parkinson's disease will be the development of therapies which slow the progression of the disease. Testing of new agents will require recruitment of recently diagnosed Parkinson's disease subjects and retention of them in therapeutic trials lasting five to ten years. The extensive experience of the Oregon Health & Science University Parkinson Center of Oregon in conducting clinical trials, specifically long trials in recently diagnosed subjects, supports our inclusion in a cooperative multicenter trial of neruoprotective agents for Parkinson's disease. We also propose a number of means by which we may increase enrollment of de novo subjects, including subjects from minority groups, and retain them in the study. In addition, long-term trials of neuroprotective agents in early Parkinson's disease offer a unique opportunity to study the natural history of family care giving, assess caregiver strain as an outcome variable for new therapeutics and identify potential interventions to reduce care giving strain. These studies will extend and expand the preliminary studies of family care giving in Parkinson's disease we have done in the Parkinson Study Group DATATOP cohort.